Mitochondrial Peptide Research

MOTS-c Benefits and Side Effects: Research Data

What mouse and cell studies report on MOTS-c, what human MOTS-c level studies can and cannot show, what FDA found on safety in 2026, and where regulators stand.

·
Fact-checked · Reviewed by Remy Research Editorial Board
Update History ▾
October 27, 2026: Initial publication, built from FDA’s 2026 MOTS-c briefing document, the July 2026 advisory-committee vote, the WADA 2027 Prohibited List, ClinicalTrials.gov and the fact-checked MOTS-c source set.
Research-use-only framing applied throughout in line with Remy editorial standards.
TL;DR — Research Summary

The MOTS-c benefits discussed online (better insulin sensitivity, less weight gain, more exercise capacity and healthy aging) come from mouse and cell studies. No peer-reviewed trial giving MOTS-c to people has been published. In mice, MOTS-c treatment prevented diet-induced obesity and insulin resistance, and late-life treatment improved physical capacity.[1][2] Human studies so far measure the body’s own MOTS-c levels, which change with age, diabetes and exercise.[3][4][2]

MOTS-c side effects in people are unknown. FDA’s 2026 review found no safety or effectiveness information in humans and proposed against allowing it in US compounding.[5] MOTS-c is not an approved medicine, WADA prohibits it at all times, and Remy Research supplies it for in-vitro laboratory research only.[6]

Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

What Is MOTS-c? A Mitochondrial Derived Peptide

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. The peptide MOTS-c is 16 amino acids long (MRWQEMGYIFYPRKLR) and is encoded in mitochondrial DNA, inside the 12S rRNA gene, rather than in nuclear DNA.[7][1] That makes it one of the mitochondrial derived peptides (MDPs), a small family of mitochondrial peptides encoded by the mitochondrial genome.[1] MOTS-c represents a case of mitochondrial signaling: a peptide encoded in mitochondria that acts elsewhere in the cell.

A University of Southern California group described the derived peptide MOTS-c in 2015 and reported that it regulates insulin sensitivity and metabolic homeostasis, with skeletal muscle as its main target organ.[1] For the full mechanism review, see the MOTS-c mitochondrial peptide research page.

How MOTS-c Acts: AMPK Activation and Metabolic Stress

In cells, MOTS-c acts on the folate cycle and the de novo purine biosynthesis pathway tied to it. Inhibiting that pathway led to AMPK activation.[1] AMP-activated protein kinase is a nutrient and cellular energy sensor that maintains energy homeostasis, raising glucose uptake and fatty acid oxidation when energy production falls short.[8] This is how MOTS-c acts on energy metabolism and energy balance in the cell models. Under metabolic stress, MOTS-c moved from the cytoplasm into the nucleus and changed nuclear gene expression, including genes for antioxidant defenses and cellular stress responses.[9] So the peptide MOTS-c, encoded in mitochondrial DNA, can act on nuclear DNA.

In muscle, a 2026 study reported that MOTS-c improved intrinsic mitochondrial function and efficiency through PGC-1α and AMPK, the same pathways linked to mitochondrial biogenesis.[10] These are laboratory studies and animal models, and they suggest how MOTS-c may regulate metabolism, not what it does in people.

MOTS-c Peptide Benefits: Effects of MOTS-c Studied So Far

MOTS-c — Claimed Benefits and the Evidence Behind Them
Claimed benefit What was reported Evidence type
Insulin sensitivity Prevented diet- and age-linked insulin resistance in mice Animal
Weight gain Less diet-induced obesity on a high-fat diet Animal
Physical capacity Better physical capacity in young and old mice Animal
Mitochondrial function Better muscle and heart mitochondrial respiration Animal, cell
Diabetes models Less islet cell senescence, delayed diabetes Animal
Exercise response Own MOTS-c rose in muscle and blood after exercise Human (levels only)

Insulin Resistance, Glucose Tolerance and Metabolic Health

The best-known MOTS-c benefits come from the 2015 mouse work: MOTS-c treatment prevented both age-dependent and high-fat-diet-induced insulin resistance, and it prevented diet induced obesity.[1] Later studies extended this to diabetes models. In animal models, MOTS-c reduced pancreatic islet cell senescence and delayed diabetes, and in type 2 diabetic heart tissue it restored mitochondrial respiration.[11][12] These are the findings behind claims that MOTS-c may improve insulin sensitivity, glucose tolerance, metabolic syndrome and fat metabolism in chronic diseases such as type 2 diabetes; none has been tested by giving MOTS-c to people.

Exercise Capacity and Age Dependent Physical Decline

A 2021 study called MOTS-c an exercise-induced, mitochondrial encoded regulator of age dependent physical decline and muscle homeostasis. In people, the body’s own MOTS-c levels rose in skeletal muscle and in blood with exercise. In mice, MOTS-c treatment improved physical performance in young animals, and treatment started late in life improved physical capacity and markers of healthy aging and healthy lifespan (healthspan).[2] This is the work behind claims that MOTS-c promotes exercise capacity and slows age related decline. A separate human study found circulating MDPs rose after a single bout of endurance exercise.[13]

Cellular Stress and Protective Effects

Cell work links MOTS-c to stress resistance: in nuclear-translocation experiments, cells with MOTS-c in the nucleus handled metabolic stress better.[9] That is the source of claims that MOTS-c helps cells adapt or builds cellular resilience. These protective effects are laboratory findings, and one 2026 cell study found a trade-off (see side effects below).[14]

Human Evidence: What MOTS-c Levels Show

Human studies measure natural MOTS-c, not the effects of MOTS-c given as a treatment. Circulating MOTS-c levels showed an age related decline in men, while MOTS-c in muscle tissue was about 1.5-fold higher in middle-aged and older men than in young men.[3] Mitochondrial derived peptides were lower in people with diabetes in a cohort from Qatar.[4] A 2026 study found the opposite pattern in obesity: systemic MOTS-c was higher in adults with obesity, in association with metabolic dysfunction, and did not change after weight loss.[15] A mitochondrial DNA variant that changes one amino acid of MOTS-c was linked to type 2 diabetes in men.[16]

These are associations, and measurement is a problem: a doping-control laboratory that built a mass-spectrometry test for plasma MOTS-c could not confirm values reported with commercial immunoassay kits.[17] The only completed industry trial in this area tested CB4211, an analogue of MOTS-c, in a phase 1 study of 88 people; results appeared only in a company press release.[18][19] No peer-reviewed human trial of MOTS-c supplementation or MOTS-c treatment has been published, so claims made for MOTS-c peptide therapy rest on animal and cell data.[5]

MOTS-c Side Effects and Safety

Is MOTS-c FDA Approved?

Where MOTS-c stands as of October 27, 2026.
  • FDA approval. No. Among regulatory bodies, FDA has reviewed MOTS-c most closely. It is not an approved drug, and FDA’s reviewers proposed not adding it to the list of substances US pharmacies may compound.[5]
  • Compounding. MOTS-c left FDA’s Category 2 safety-risk list because its nomination was withdrawn.[21] On July 23, 2026 FDA’s advisory committee voted 7 to 5, with two abstentions, to recommend adding it; the vote is non-binding.[22] An FDA interim access policy for certain peptides has been under White House review since October 14, 2026, with no final action yet.[23]
  • Sport. WADA names MOTS-c under S4.4.1, activators of AMPK, on the 2027 Prohibited List, prohibited at all times.[6]
  • UAE. MOTS-c is not a registered medicine. Remy Research sells it for in-vitro laboratory research only, not for human or veterinary use.

MOTS-c vs Other Mitochondrial Peptides

MOTS-c is often compared with SS-31 (elamipretide) and with AICAR. SS-31 is a synthetic four-residue peptide that binds the inner mitochondrial membrane and is FDA-approved for Barth syndrome; MOTS-c is a natural peptide encoded in mitochondrial DNA with no human trial. See MOTS-c vs SS-31 and SS-31 benefits and side effects.

AICAR is a small molecule, not a peptide, that activates AMPK directly; WADA lists both in the same class.[6] The differences are covered in AICAR vs MOTS-c and the AICAR research review.

What MOTS-c Research Does Not Yet Show

These gaps are not arguments against MOTS-c research. They are arguments against overselling it.

MOTS-c for Laboratory Research

Remy Research supplies MOTS-c for in-vitro research as the MOTS-c 10mg research vial, the MOTS-c 20mg pen and the Genovare MOTS-c 25mg AQ pen. Each product page carries its batch testing details. For UAE availability and supplier checks, see the MOTS-c Dubai guide.

Our Research Standards

This article prioritizes primary literature, trial registries and regulator records, and keeps cell, animal and human evidence apart. Where the human record is empty, we say so directly. No therapeutic, dosing or administration guidance is given. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

MOTS-c Benefits and Side Effects FAQ

What are the benefits of MOTS-c?

In mice, MOTS-c prevented diet-induced obesity and insulin resistance and improved physical capacity in old age. No trial has shown these benefits in people.[1][2]

What are the side effects of MOTS-c?

They are unknown. FDA found no safety information in humans and could not rule out immune reactions to impurities or aggregates.[5]

Is MOTS-c safe?

Its safety in people has not been studied. FDA said potential risks in humans are unknown, and the lack of reported side effects reflects the lack of human studies.[5]

Is MOTS-c FDA approved?

No. An FDA advisory committee voted 7 to 5 in July 2026 to recommend allowing it in compounding, against the advice of FDA’s reviewers; the vote is non-binding and no final action had followed by October 27, 2026.[22][23]

What does MOTS-c do in the body?

The body makes it from mitochondrial DNA. In cells it activates AMPK through the folate and purine pathways and, under metabolic stress, enters the nucleus to change gene expression.[1][9]

Does MOTS-c help with fat loss?

In mice on a high-fat diet it prevented weight gain. There are no human data on MOTS-c and body fat, and natural MOTS-c levels were higher, not lower, in adults with obesity.[1][15]

Is MOTS-c banned in sport?

Yes. WADA lists it under S4.4.1, activators of AMPK, prohibited at all times, and a mass-spectrometry detection method exists.[6][17]

Is MOTS-c the same as AICAR?

No. MOTS-c is a 16-amino-acid peptide; AICAR is a small-molecule nucleoside. Both activate AMPK and both are on WADA’s S4.4.1 list.[7][6]

Sources

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi: 10.1016/j.cmet.2015.02.009 · PMID: 25738459 ↩
  2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. doi: 10.1038/s41467-020-20790-0 · PMID: 33473109 ↩
  3. D’Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020;12(6):5244-5258. doi: 10.18632/aging.102944 · PMID: 32182209 ↩
  4. Ramanjaneya M, Bettahi I, Jerobin J, et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol (Lausanne). 2019;10:331. doi: 10.3389/fendo.2019.00331 · PMID: 31214116 ↩
  5. U.S. Food and Drug Administration. FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate). Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. fda.gov/media/193347 ↩
  6. World Anti-Doping Agency. The 2027 Prohibited List (in force January 1, 2027), S4.4.1: activators of AMPK, including AICAR and mitochondrial open reading frame of the 12S rRNA-c (MOTS-c). wada-ama.org ↩
  7. UniProt. A0A0C5B5G6 (MOTSC_HUMAN), Mitochondrial-derived peptide MOTS-c, 16 aa, sequence MRWQEMGYIFYPRKLR, encoded by MT-RNR1 (12S rRNA). uniprot.org/uniprotkb/A0A0C5B5G6 ↩
  8. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262. doi: 10.1038/nrm3311 · PMID: 22436748 ↩
  9. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. doi: 10.1016/j.cmet.2018.06.008 · PMID: 29983246 ↩
  10. Gudiksen A, Hansen CC, van der Stede T, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026;246:682-696. doi: 10.1016/j.freeradbiomed.2026.01.002 ↩
  11. Kong BS, Lee H, L’Yi S, Hong S, Cho YM. Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Exp Mol Med. 2025;57(8):1861-1877. doi: 10.1038/s12276-025-01521-1 ↩
  12. Pham T, Taberner A, Hickey A, Han JC. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Front Physiol. 2025;16:1602271. doi: 10.3389/fphys.2025.1602271 ↩
  13. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042. doi: 10.1152/japplphysiol.00706.2019 · PMID: 34351816 ↩
  14. Xing L, Lu B, Zhu X, et al. Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells. Inflamm Regen. 2026;46(1):35. doi: 10.1186/s41232-026-00431-7 ↩
  15. Yoon SH, Yuan F, Zhu X, et al. Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. J Clin Transl Endocrinol. 2026;43:100429. doi: 10.1016/j.jcte.2025.100429 ↩
  16. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. doi: 10.18632/aging.202529 · PMID: 33468709 ↩
  17. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Commun Mass Spectrom. 2019;33(4):371-380. doi: 10.1002/rcm.8337 · PMID: 30394592 ↩
  18. ClinicalTrials.gov. NCT03998514, Phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with NAFLD (completed; 88 enrolled; record checked October 27, 2026). clinicaltrials.gov/study/NCT03998514 ↩
  19. CohBar, Inc. CohBar announces positive topline results from the Phase 1a/1b study of CB4211 (press release), August 10, 2021. globenewswire.com ↩
  20. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. doi: 10.1007/s40279-026-02437-0 · PMID: 41966639 ↩
  21. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (MOTs-C listed under “nominated but withdrawn”). Content current as of April 22, 2026. fda.gov ↩
  22. Jacobus N. FDA panel votes to loosen restrictions for four peptides (MOTS-c recommended 7-5 with two abstentions). Pharmaceutical Executive, July 24, 2026. pharmexec.com ↩
  23. Office of Information and Regulatory Affairs. Pending EO 12866 Regulatory Review: Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94; HHS/FDA; received October 14, 2026; still pending when checked October 27, 2026). reginfo.gov ↩

For catalog details, see the MOTS-c 10mg research vial, the MOTS-c 20mg pen and the Genovare MOTS-c 25mg AQ pen. For editorial standards, continue to the editorial policy.

Research products mentioned in this article

Product Genovare AICAR 250mg AQ Pen→ Product ProPeptide SS-31 Vial 50mg→ Product ProPeptide SS-31 40mg Pen→ Product Genovare SS-31 100mg AQ Pen→

Related Research

Catalog MOTS-c 10mg Research Vial→ Catalog MOTS-c 20mg Pen→ Catalog Genovare MOTS-c 25mg AQ Pen→ Research MOTS-c Mitochondrial Peptide Research→ Comparison MOTS-c vs SS-31→ Metabolic AICAR AMPK Activator Research→ UAE MOTS-c Dubai Guide→ Catalog Research Peptide Catalog→